Rekombinanter ErbB2/Her2 (Trastuzumab Biosimilar) Antikörper
Reaktivität: Human
FACS, ELISA, IHC
Wirt: Human
Monoclonal
4D5-8
unconjugated
Recombinant Antibody
(1 reference)-
- Target Alle ErbB2/Her2 (Trastuzumab Biosimilar) Produkte
- ErbB2/Her2 (Trastuzumab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human
-
Wirt
-
Human
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser ErbB2/Her2 (Trastuzumab Biosimilar) Antikörper ist unkonjugiert
-
Applikation
- Flow Cytometry (FACS), ELISA, Immunohistochemistry (IHC)
- Spezifität
- Oncogenic protein Her-2/neu (erbB-2), a member of the family of epidermal growth factor (EGF) receptors, overexpressed in 30 % of invasive breast cancers and 70 % of ductal carcinomata in situ, in a small percentage of melanomas, and in other malignancies originating from various organs, including ovary, kidney, colon, and bladder.
- Produktmerkmale
-
OriginalSpeciesName: Human
OriginalFormat: IgG1
- Aufreinigung
- Purified antibody.
- Reinheit
- > 98 % as determined by SDS-PAGE
- Endotoxin-Niveau
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
- Immunogen
- A431 cells (human epidermoid carcinoma) (over)expressing EGFR.
- Klon
- 4D5-8
- Isotyp
- IgG1 kappa
-
anti-ErbB2/Her2 (Trastuzumab Biosimilar) antibody
Reaktivität: Human FACS, ELISA, IHC Wirt: Kaninchen Monoclonal 4D5-8 unconjugated Recombinant Antibody
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Kommentare
-
NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- PBS with 0.02 % Proclin 300.
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
-
: "Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer." in: Journal of translational medicine, Vol. 17, Issue 1, pp. 201, (2020) (PubMed).
-
: "Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer." in: Journal of translational medicine, Vol. 17, Issue 1, pp. 201, (2020) (PubMed).
-
- Target
- ErbB2/Her2 (Trastuzumab Biosimilar)
- Abstract
- ErbB2/Her2 (Trastuzumab Biosimilar) Produkte
- Synonyme
- CD340 antikoerper, HER-2 antikoerper, HER-2/neu antikoerper, HER2 antikoerper, MLN 19 antikoerper, NEU antikoerper, NGL antikoerper, TKR1 antikoerper, erb-b2 receptor tyrosine kinase 2 antikoerper, ERBB2 antikoerper
- Substanzklasse
- Biosimilar
- Hintergrund
- CD340, Metastatic lymph node gene 19 protein (MLN 19), Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, p185HER2, EGFR
- UniProt
- P04626
-
Sie sind hier:
